Compare Novartis AG (NVS) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Warner Music Group Corp — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Warner Music Group Corp trades at $28.2 (market cap $14.64B). The key difference: Novartis AG is far larger — about 19.8× Warner Music Group Corp's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | WMG | |
|---|---|---|
Market Cap | $290.25B | $14.64B |
Sector | Health | Media |
52-Week High | $168.62 | $34.72 |
52-Week Low | $113.50 | $23.65 |
Enterprise Value | $330.27B | $18.84B |
Dividend Yield | 3.17% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Warner Music Group (WMG) trades at $27.945, down 1.36% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with a Q1 2026 beat but recent quarterly misses. Revenue growth is steady, reaching $6.71B in 2025, though net income margin has compressed to 5.44%. Recent strategic moves include a licensing renewal with NetEase Cloud Music and the acquisition of AI startup Sureel AI, positioning the company for growth in digital and AI-driven music markets.
WMG presents a compelling long-term opportunity with analyst consensus pointing to significant upside (target $41.00), supported by 66.66% buy ratings. However, risks include competitive pressures in streaming, margin volatility, and execution challenges in integrating AI technologies. The stock's current valuation multiples (P/E 33.4) suggest premium pricing relative to earnings, requiring sustained growth to justify investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
